Sequenom Stock Surges 13 Percent on Positive Study Results | GenomeWeb

NEW YORK, March 27 (GenomeWeb News) - Shares in Sequenom were up 13.29 percent, or $.09, at $.75 in mid-afternoon trading today after the company said two proof-of-concept molecular diagnostic studies using its MassArray system have garnered positive results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.